Martin Sendzik

USPTO Granted Patents = 38 (Patent Applications = 15)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 7.9

ph-index = 9

Forward Citations = 243(Granted Patents)

Location History:

San Mateo, CA (US) (2005 - 2016)
Belmont, MA (US) (2017 - 2024)

Company Filing History:

Novartis Vaccines & Diagnostics, Gmbh

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

38 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12209098 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2025-01-28),

2. 11952386 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2024-04-09),

3. 11931363 - Triazolopyrimidine compounds and uses thereof (2024-03-19),

4. 11905283 - Compounds and compositions for inhibiting the activity of SHP2 (2024-02-20),

5. 11207325 - Triazolopyrimidine compounds and uses thereof (2021-12-28),

6. 10968235 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2021-04-06),

7. 10934285 - Compounds and compositions for inhibiting the activity of SHP2 (2021-03-02),

8. 10689378 - Triazolopyridine compounds and uses thereof (2020-06-23),

9. 10676479 - Imidazolepyridine compounds and uses thereof (2020-06-09),

10. 10336774 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2019-07-02),

11. 10308660 - Compounds and compositions for inhibiting the activity of SHP2 (2019-06-04),

12. 10301278 - 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 (2019-05-28),

13. 10287266 - Compounds and compositions for inhibiting the activity of SHP2 (2019-05-14),

14. 10220036 - Triazolopyrimidine compounds and uses thereof (2019-03-05),

15. 10167279 - Compounds and compositions as RAF kinase inhibitors (2019-01-01),

Title: Innovator Spotlight: Martin Sendzik Revolutionizing Healthcare in San Mateo

Introduction:

Martin Sendzik, a prolific inventor hailing from San Mateo, CA, is making waves in the field of healthcare with his groundbreaking patents and innovative research. With a remarkable track record of 34 patents, Martin is a driving force behind cutting-edge advancements in medicine.

Latest Patents:

Among his latest patents, Martin has made significant contributions to the medical field with inventions such as Triazolopyrimidine compounds for treating PRC2-mediated diseases and N-azaspirocycloalkane substituted N-heteroaryl compounds for inhibiting the activity of SHP2. These inventions showcase his expertise in developing novel treatments for complex diseases.

Career Highlights:

Martin Sendzik has honed his skills and expertise while working at prestigious companies such as Novartis AG and Pharmacyclics, Inc. His experience in these leading organizations has not only expanded his knowledge but also provided him with a platform to bring his revolutionary ideas to life.

Collaborations:

Throughout his career, Martin has collaborated with distinguished professionals in the industry, including Zhuoliang Chen and James Clifford Sutton. These partnerships have been instrumental in driving innovation and pushing the boundaries of scientific discovery in healthcare.

Conclusion:

In conclusion, Martin Sendzik stands out as a visionary inventor whose contributions are shaping the future of healthcare. His dedication to revolutionizing treatments for complex diseases and disorders exemplifies his commitment to making a meaningful impact on society. As he continues to push the boundaries of innovation, Martin remains a driving force in the quest for new advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.